Safety and Efficacy of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars

ConditionAtrophic Scar
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age19+
SponsorCellinCells

About this trial

The purpose of this clinical trial was to evaluate the safety and efficacy of a single administration of TRTP-101 in adults with atrophic scars.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Male or Female aged greater than 19 years

Acne scars graded ≥ 3 on the 5-point ASRS

Four or more atrophic scars in the joints, genitals, perineum, and face except for the lips, eyes and nose

Atrophic scar lesions approximately 2 cm in diameter located on the cheeks or temple on both sides of the face

Disqualifiers

History of cell therapy

Treatment of Dermal resurfacing, Chemical/Mechanical Peel and Skin Photorejuvenation

Treatment of Hyaluronic acid/collagen skin filler, non-permanent soft tissue filler and fat grafting

Positive for virus infection

Trial design

Design model

Parallel

Treatments tested in this trial

  • TRTP-101

    Biological/Vaccine

    Intradermal injection

  • Placebo

    Biological/Vaccine

    Intradermal injection

Treatment groups

31 Participants
are divided into 5 treatment groups
Group A: TRTP-101Experimental treatment 1 intervention
Group B: TRPT-101 (Low dose group)Experimental treatment 1 intervention
Group C: Placebo (Low dose group)Placebo comparator 1 intervention
Group D: TRPT-101 (High dose group)Experimental treatment 1 intervention
Group E: Placebo (High dose group)Placebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

[Phase 1] Number of Subjects with Dose Limiting Toxicity

Dose Limiting Toxicity is defined as Grade ≥ 3 adverse drug reaction according to CTCAE criteria for 4 weeks after administration of TRTP-101

Time frame
within 4 weeks
2

[Phase 2] Proportion of subjects achieving ≥ 1-grade improvement from baseline in ASRS

Proportion of subjects with ≥ 1-grade improvement from baseline in ASRS (Acne Scar Rating Scale) at 12, 24 weeks after treatment, as assessed by independent reviewers using a standardized photoguide \*The Acne Scar Rating Scale (ASRS) is a 5-grade scale ranging from 0 to 4 (0 = Clear, 1 = Very mild, 2 = Mild, 3 = Moderate, and 4 = Severe). Higher grades indicate greater severity of atrophic scars and therefore a worse outcome.

Time frame
12, 24 weeks after treatment

Secondary outcomes

1

[Phase 2] Proportion of subjects achieving ≥ 1-grade improvement on the GAIS

Proportion of subjects with ≥ 1-point improvement from baseline on the GAIS (Global Aesthetic Improvement Scale) at 12, 24 weeks after treatment, as assessed by independent reviewers. \*The Global Aesthetic Improvement Scale (GAIS) is a 5-grade scale ranging from -1 to 3 (-1 = Worse, 0 = No change, 1 = Improved, 2 = Much improved, and 3 = Very much improved). Higher grades indicate greater aesthetic improvement and therefore a better outcome.

Time frame
12, 24 weeks after treatment
2

[Phase 2] Distribution of subjects by treatment satisfaction score

Distribution of subjects by treatment satisfaction score at 12, 24 weeks after treatment, assessed using the Subject Acne Scar Self-Assessment Scale. \*The Subject Acne Scar Self-Assessment Scale is a 5-grade scale ranging from -2 to +2 (-2 = Very dissatisfied, -1 = Dissatisfied, 0 = Somewhat satisfied, +1 = Satisfied, and +2 = Very satisfied). Higher grades indicate greater satisfaction with acne scars and therefore a better outcome.

Time frame
12, 24 weeks after treatment

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.